CTRI/2020/02/023099已完成2 期
A Phase II, prospective, multi-center, randomized, 4-week, double-blind, placebo-controlled, multiple-dose study, designed to determine the safety, tolerability, EEG effects and preliminary efficacy of fixed oral doses of 7.5 and 15 mg bid of evenamide (NW-3509) in patients with chronic schizophrenia who are symptomatic on their current second-generation antipsychotic (aripiprazole, clozapine, quetiapine, olanzapine, paliperidone, or risperidone) medication.
ewron Pharmaceuticals SpA0 个研究点目标入组 111 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 111
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Psychiatric
- •4.Has a current diagnosis of schizophrenia in accordance with DSM-5. Other Axis-I disorders may be present only as lifetime diagnoses if they are not relevant to the current episode of schizophrenia. [see Exclusion criteria below]
- •5.Has been treated with antipsychotics for at least 2 years.
- •6.Has a total score on the PANSS < 80.
- •7.Has a Clinical Global Impression â?? Severity of disease (CGI-S) rating of mildly, moderately or moderately severely ill (score of 3, 4 or 5).
- •8.Needs antipsychotic treatment and is currently receiving a stable dose (minimally for 4 weeks prior to screening) of aripiprazole, clozapine, quetiapine, olanzapine, paliperidone, or risperidone (at least 2 mg risperidone dose-equivalent).
- •9.Current symptoms have been stably present for at least one month.
- •10.Patient has provided written informed consent prior to participating in the study.
- •11.Patient is able to take oral medication and is willing to complete all protocol-defined aspects of the study.
- •12.Patient resides at home or in a residential care facility with a caregiver who is available to ensure compliance with dosing and scheduled office visits. For US only: â??Caregiverâ?? is defined as someone who has at least 5 contacts with the patient each week, of which at least 2 are face-to-face.
- •13.Patient agrees to be hospitalized overnight if required for trial purposes or if the investigator deems it necessary to ensure the safety of the patient.
- •14.If taking clozapine, patient agrees to blood monitoring (venipuncture for measuring ANC) weekly during their first 6 months of clozapine treatment, every 2 weeks from 6 to 12 months, and every 4 weeks after 12 months of treatment.
排除标准
- •Psychiatric
- •1.DSM-5 diagnosis of schizophreniform disorder (295.40), schizoaffective disorder (295.70), or other primary psychiatric diagnosis, such as bipolar disorder or major depressive disorder. (Comorbid depression will be assessed at screening and baseline using the Calgary Depression Scale for Schizophrenia [CDSS]. A score of 7 or higher will be exclusionary.)
- •2.History (within three months of study entry) or current diagnosis of Substance Use Disorder as defined by the DSM-5 criteria, with a severity of â??moderateâ?? or â??severeâ??, or patient is currently abusing drugs or alcohol or has done so in the past year. A history of nicotine or caffeine dependence is acceptable
- •3.Severity of current episode of psychosis requires that the patient be hospitalized. Patients who are chronically hospitalized or in psychiatric day-care, whose hospitalization is for logistic reasons and not due to the severity of their illness, will be eligible for the study.
- •4.Severity of psychosis is rated severe or higher (CGI-S of 6 or greater).
- •5.History or current diagnosis of other psychiatric (Axis I diagnosis) or behavioral disorders that may interfere with the conduct or interpretation of the study.
- •6.Known suicidal risk. A â??yesâ?? response on the C-SSRS Suicidal Ideation Item 4 or Item 5, or a â??yesâ?? response on any of the five C-SSRS Suicidal Behavior items, at screening, or a suicide attempt within the past 6 months, excludes the patient from the study.
- •7.â??Treatment resistantâ?? defined significant persistent symptoms of schizophrenia after adequate doses of two standard antipsychotic medications (from two different chemical classes, including at least one atypical antipsychotic) following 6 weeks of treatment with each at adequate doses. Treatment resistant patients on clozapine for at least 6 months will be permitted if they have shown minimal improvement in the Investigatorâ??s judgement.
- •8.History of neuroleptic malignant syndrome, priapism.
- •9.History of severe tardive dyskinesia; or current moderate or severe tardive dyskinesia.
- •Medical Status
- •10.Abnormal epileptiform phenomena (3 per second spike and slow wave discharges) observed on screening EEG.
- •11.An advanced, severe, or unstable disease of any type that may interfere with any of the study evaluations, including any medical condition that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical or mental status of the patient to a significant degree or put the patient at special risk (e.g., respiratory, liver or kidney disease; malignancy);
- •12.A disability that may prevent the subject from completing all study requirements (e.g., blindness, deafness, severe language difficulty);
- •13.Insulin-dependent diabetes mellitus. Patients with non-insulin-dependent diabetes will be eligible if the following criteria are satisfied:
研究者
相似试验
已完成
2 期
A clinical study to determine safety, tolerability and efficacy of drug called Evenamide which is taken orally, in patients with long standing schizophrenia getting inadequate benefit from their current antipsychotic medication.CTRI/2021/04/032772ewron Pharmaceuticals SpA112
招募中
1 期
A phase-2, multi-centre, prospective, randomized, standard-of-care plus placebo-controlled, patient and central evaluator blinded, parallel arm, clinical study to evaluate safety, tolerability and efficacy of the recommended phase-2 dose of AUP1602-C in two dosing frequencies as a topical treatment for non-healing neuro-ischemic diabetic foot ulcersdiabetic foot ulcersMedDRA version: 21.1Level: LLTClassification code: 10012664Term: Diabetic foot ulcer Class: 10040785CTIS2022-502048-10-00Aurealis Oy100
进行中（未招募）
1 期
Multi center clinical study to evaluate the safety and efficacy of CB-03-01 for the treatment of female pattern hair loss, versus Minoxidil and placebo at different dosage of CB-03-01EUCTR2019-000950-78-DECassiopea S.p.A.280
进行中（未招募）
不适用
Study on the effect of vitamin D in women at high risk of developing breast cancer.Women at high risk of developing breast cancerEUCTR2011-002162-21-ESJosé Esteban Castelao Fernández
已完成
不适用
A Phase II Prospective, Randomized, Multi-Center, Diabetic Macular Edema Dose Ranging, Comparator Study Evaluating The Efficacy And Safety Of PF-04523655 Versus Laser Therapy (DEGAS)-H36-E103 Insulin-dependent diabetes mellitus, with ophthalmic complications-E113 Non-insulin-dependent diabetes mellitus, with ophthalmic complicationsInsulin-dependent diabetes mellitus, with ophthalmic complicationsNon-insulin-dependent diabetes mellitus, with ophthalmic complicationsE103E113H36PER-153-08PFIZER S.A.,